ReviewNutrients2025
Tracking Evidences of Dandelion for the Treatment of Cancer: From Chemical Composition, Bioactivity, Signaling Pathways in Cancer Cells to Perspective Study.
Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultrasound-engineered chitosan nanocarriers improve the anticancer activity of dandelion phytochemicals in hepatocellular carcinoma cells.Frontiers in pharmacology · 2026Article
- Extracellular vesicle-like particles fromFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cancer has become the second leading cause of death globally and is a big threat to human health. The development of new anticancer drugs and the elucidation of the signaling pathways of bioactive compounds are still effective strategies to address the current challenges in the clinical treatment of cancer. Dietary compounds are composed of a variety of effective ingredients, which have become an important source for the development of novel candidates for the treatment of cancer. These bioactive ingredients often carry the characteristics of low side effects, multi-target, and economic savings and hence attract more and more scholars' research interests in them. Dandelion, one of the important medicinal and edible plants, is effective in anticancer, inhibition of bacterial growth, hypoglycemic, and anti-inflammation, as well as antioxidant. Growing evidences from modern pharmacological research demonstrate the notable anticancer effects of dandelion. Bioactive components from dandelion are effective in inhibiting the occurrence and progression of various cancers, such as breast, lung, and liver cancers. Hence, the chemical composition, anticancer activities, and signaling pathways in cancer cells treated with bioactive components from dandelion are summarized in this review. We aim to provide more pharmacological evidence and scientific references for further research and development of dandelion for cancer treatment. Meanwhile, we anticipate that some novel candidates with high efficacy and low toxicity for anticancer might be developed from dandelion in future research on this plant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.